Jose L. Pedrini
Porto Alegre, RS, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Optimizing breast cancer therapy: chemoressitance and machine learning for precision prediction.
Journal: Personalized medicine
Published: July 16, 2025
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 21, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Journal: Nature medicine
Published: March 29, 2024
Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.
Journal: BMC cancer
Published: July 16, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 28, 2022
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Journal: The New England journal of medicine
Published: March 23, 2022
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 19, 2017
A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients.
Journal: Clinics (Sao Paulo, Brazil)
Published: May 10, 2016
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Journal: The Lancet. Oncology
Published: December 23, 2015
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 10, 2015
Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
Journal: Journal of the National Cancer Institute
Published: December 10, 2013
How to identify patients with increased risk of breast cancer relapse?
Journal: Applied immunohistochemistry & molecular morphology : AIMM
Published: August 21, 2013
Last Updated: 09/26/2026